Filtered By:
Condition: Bleeding
Countries: Canada Health
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 136 results found since Jan 2013.
Mechanical versus bioprosthetic valves in chronic dialysis: a systematic review and meta-analysis
CONCLUSION: Mechanical valves were associated with reduced mortality, but increased rate of bleeding and stroke. Given very low certainty for evidence of mortality and stroke outcomes, patients and clinicians may choose prosthetic valves based on factors such as bleeding risk and valve longevity.STUDY REGISTRATION: PROSPERO no. CRD42017081863.PMID:35820696 | PMC:PMC9293484 | DOI:10.1503/cjs.001121
Source: Canadian Journal of Surgery - July 12, 2022 Category: Surgery Authors: Kevin S Kim Emilie P Belley-C ôté Saurabh Gupta Arjun Pandey Ali Alsagheir Ahmad Makhdoum Graham McClure Brooke Newsome Sophie W Gao Matthias Bossard Tetsuya Isayama Yasuhisa Ikuta Michael Walsh Amit X Garg Gordon H Guyatt Richard P Whitlock Source Type: research
Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study
CONCLUSIONS: Despite universal health care and prescription medication coverage, residents of more deprived neighborhoods were less likely to visit cardiologists or receive rhythm control interventions after AF diagnosis, even though they exhibited higher cardiovascular disease burden and higher risk of adverse outcomes.PMID:35678171 | DOI:10.1161/CIRCULATIONAHA.122.058949
Source: Circulation - June 9, 2022 Category: Cardiology Authors: Husam Abdel-Qadir Leo E Akioyamen Jiming Fang Andrea Pang Andrew C T Ha Cynthia A Jackevicius David A Alter Peter C Austin Clare L Atzema R Sacha Bhatia Gillian L Booth Sharon Johnston Irfan Dhalla Moira K Kapral Harlan M Krumholz Candace D McNaughton Ida Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations
Eur J Intern Med. 2022 May 4:S0953-6205(22)00166-2. doi: 10.1016/j.ejim.2022.04.023. Online ahead of print.ABSTRACTClinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the past 3 years, various new AF guidelines or focused updates have been published, given this rapidly evolving field. In 2019, the American College of Cardiology/American Heart Association published a focused update of the 2014 guidelines. In 2020, both the European Society of Cardiology and the Canadian Cardiovascular Society released their new guidelines. Finally, the most recent guidelines were those published in 20...
Source: European Journal of Internal Medicine - May 7, 2022 Category: Internal Medicine Authors: Jacopo Francesco Imberti Davide Antonio Mei Marco Vitolo Niccol ò Bonini Marco Proietti Tatjana Potpara Gregory Y H Lip Giuseppe Boriani Source Type: research
Variation in bleeding risk estimates among online calculators: Cross-sectional study of apps used by and for patients with atrial fibrillation
CONCLUSION: Inconsistencies and a lack of precision were observed in annual risk estimates and risk stratification produced by Web and mobile bleeding risk calculators for patients with atrial fibrillation. Clinicians should refer to annual bleeding risks observed in major randomized controlled trials to inform risk estimates communicated to patients.PMID:35418403 | PMC:PMC9007121 | DOI:10.46747/cfp.6804e127
Source: Canadian Family Physician Medecin de Famille Canadien - April 14, 2022 Category: Primary Care Authors: Ryan Pelletier Jeff Nagge John-Michael Gamble Source Type: research
